Cell Therapy News

Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.

Subscribe|Follow Us On

Adoptive γδ T Cell Therapy Controls Cytomegalovirus Infection in Preclinical Transplantation Models

February 18, 2026

[Nature Communications] Scientists assessed a Vδ1 + γδ T cell-based adoptive cell therapy, named Delta One T cells, to treat cytomegalovirus infection in high-risk transplant recipients.

Cellares and University of Wisconsin School of Medicine and Public Health Expand Partnership to Clinical Manufacturing of CRISPR-Edited CAR-T for Solid Tumors

February 18, 2026

[Cellares (Business Wire, Inc.)] Cellares and the University of Wisconsin School of Medicine and Public Health announced an expansion of their partnership to support clinical production and regulatory advancement of the university’s CRISPR-edited GD2 CAR-T investigational therapy for pediatric and adult solid tumors.

Clinical Progress of Engineered Cellular Immunotherapies for Autoimmunity

February 18, 2026

[Nature Biotechnology] The authors review the clinical progress of engineered cellular immunotherapies for autoimmunity, focusing on how antigenic target, engineered cell type, CAR design, and treatment regimens affect the therapeutic efficacy and safety of these treatments.

Engineering Chimeric Antigen Receptor CD4 T Cells for Alzheimer’S Disease

February 18, 2026

[Proceedings of the National Academy of Sciences of the United States of America] Scientists engineered CD4+ T cells with CARs targeting fibrillar forms of aggregated amyloid-β.

Gyala Therapeutics Initiates Phase I/IIa Clinical Trial of a CAR-T Cell Therapy in Acute Leukemias with Limited Treatment Options

February 18, 2026

[Gyala Therapeutics (PR Newswire)] Gyala Therapeutics announced the initiation of a Phase I/IIa clinical trial of GYA01 following authorization from the Spanish Agency of Medicines and Medical Devices (AEMPS).

T Cell-Targeted Fusogenic Nanovesicles Generate CAR-T Cells In Vivo for Rheumatoid Arthritis Therapy

February 18, 2026

[Biomarker Research] Researchers developed FuNVCAR, a T cell-targeted fusogenic nanovesicle system that delivers preformed αCD19 CAR proteins to T cells via membrane fusion.

High Efficiency CRISPR Knock-in Demonstrates That TCF1 Is Insufficient to Reverse T Cell Exhaustion

February 18, 2026

[Nature Communications] Scientists engineered T cells that either constitutively over-express TCF1, or conditionally over-express TCF1 following differentiation of the cells into a CX3CR1+ intermediate-exhausted state.

T Cells Engineered against Dickkopf-1-A2 Complex Can Be Used to Treat HLA-A2 Solid and Hematologic Cancers

February 18, 2026

[Nature Communications] The authors generated DKK1-A2 CAR-T cells that specifically and effectively lyse HLA-A2- and DKK1-expressing tumor cells but not blood or bone marrow cells from HLA-A2+ healthy donors.

Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models

February 18, 2026

[Blood Cancer Discovery] Knockout studies revealed that endogenous CD28 on 4-1BB co-stimulated CAR T cells prolonged in vivo activity, reprogrammed mitochondrial metabolism to maintain redox balance, and stimulated proliferation and release of tumor-model specific inflammatory cytokines in the tumor microenvironment.

Toward CAR T Cell Therapy: Perfecting CAR and Lipid Nanoparticle Design

February 12, 2026

[Nano Letters] The authors review the molecular and mechanistic principles underlying in vivo CAR-T cell therapy, emphasizing how these nanoscale design features govern CAR T cell production and functional performance in vivo.

Ablation of Prostaglandin E2 Signalling through Dual Receptor Knockout in CAR T Cells Enhances Therapeutic Efficacy in Solid Tumours

February 12, 2026

[Nature Biomedical Engineering] Investigators generated knockout CAR T cells double deficient for the PGE2 receptors EP2 and EP4 by CRISPR–Cas9 engineering.

Michel Sadelain Awarded BBVA Foundation Frontiers of Knowledge Prize for Revolutionizing Cancer Treatment with Cell Therapies

February 12, 2026

[Columbia University Irving Medical Center] Dr. Michel Sadelain has been awarded a BBVA Foundation Frontiers of Knowledge Prize in Biology and Biomedicine for revolutionizing cancer treatment with CAR-T cell therapy, which modifies a patient’s own T cells to seek and destroy cancer cells.

Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.